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Metho& New kload While rabbits were subjected to 30 mia 
of camaary ac&sii, fGuowerJ by 5.5 b of rcperfkion. Fifteen 
mbu& before replrusion, the a&a& were randomized to 
K&P. 1) saline whdioo (caatml animals, II q 8): 2) SQ 29548, a
potent and selective lhwnboxaae A#Xi, reqdor aaiagonisI 
(a = S); 3) duoxibea, a wI?ctirc Uuwmboxaae AI syntbw 
inbibitw (n = 8); 4) R 68070 (Tfidogrel), B drug with dual 
tbroa&mne A2 syotbase-bthibiting ahd tbmmboxaoe A$?‘C& 
r_pkyblo&ng properties (a = 8); or 5) aspirin + R 68070 
&w&s. Dazoaiben and R 68070, but not SQ 29548, signili- 
cantly redwed thmmboxaae Bz formation aad iocreawd plasma 
Several studies suggest that activ%ion of the arachidonic 
acid cascade may play an important role in the pathophysi- 
ology of myocardiai injury during ischemia and reperfusion. 
lhllas, 
Texas, November l!M. 
m: Pado Golino, MCI. LMiaian ofCardiology. 
2nd kboolofhtcdicine. Univenily of Naples. Via S. hnsini 5,80131 Naples. 
My. 
avemgolng 59.7 f 1.6% (p = NSOS. 
ia regional myCGwdial bkad Row, 
rate or exleai Of awe a1 risk were 
For instance. it has been shown that mvocardiai ischemia 
may activate phospholipase AZ, with consequent release of 
free arachidonic acid from cell membranes (1). Tbrombox- 
ane A:, rhe main product of arachidanic acid metabolism in 
platelets, can exacerbate the progression of ischemia- 
induced myocardial damage (2.3) and the occurrence of fatal 
ventricular arrhythmias (4.5). In addition, increased throm- 
boxane A, formation has been associated with unstable 
angina (6) and possibly other forms ofischemic heart diseax 
(7). These observations have led to speculation that inhibi- 
tion of thromboxane A, formation or prevention of its effects 
may lead fo a reduction of ischemia-induced myowdial 
damage. However. early attempts aimed ar rednciog the 
irchemic damage by inhibikg thromboxaoe A, forma&n 
with cyclooxygenase inhibitors such as aspirin were usually 
Figure I. Schematic representation of the arachidonic acid cascade 
and drugs used in the present study to block the formation oraclion 
of thromboxane A. tTxA.1. Asoiria. bv blockine cvclo~.v~enase. 
prevents further deiabfm ok a&d.& a&, ‘thus i%bit& 
bolh thromboxane A, and pmsraplsndin Wi) formation. Selective 
syntbase inhibition maybe shunted lo;/srd the synthesis olF’GD~~ 
PGE, and PG& tJ&hed arrows). In addition, PGW, itself may 
directly stimulate the ane rere~lor shared with thmmboxane A, 
(Ii&t gray amew). Finally. the effects of thromboxane A, can & 
prevented by selective thromboxaae AJPGH, receptor antagonists. 
unsuccessful (S-IO), probably because of a simultaneous 
inhibition of prostaglandin (PG) I, production (1 I). 
An alternative approach is provided by the development 
of selective inhibitors of thromboxane AZ synthase, the 
enzyme responsible ior the conversion of prostaglandin 
endoperoxides to thromboxane A,. These drugs have the 
advantage over cyclooxygenase inhibitors that they not only 
reduce the formation of thromhoxane A2 but additionally 
reorient the metabolism o: accumulated prostaglandin en- 
doperoxides into incrtised amounts of PC&, PGDz and 
PGE, (12,13). A cariety of such drugs have been demon- 
stralcd to be ‘Jeneticial in experimental models of acute 
myocardial lschemia as assessed by various indexes of 
myocellular iiury (2.3.14). Recently, it has been suggested 
that the protective effects of thromboxane A, synthase 
inhibitors on ischemic myocardium are largely mediated by a 
redirection of pros!aglandin endoperoxides (which cannot be 
metabolized to thromboxane A, as a consequence of the 
distal block of thromboxane A, synthase) toward the syn- 
thesis of “cardioprotective” prostaglandins, such as ffil,, 
PGD, and PGE, (Fig. I) (IS). However, part of these 
prostaslandin endoperoxides may also activate a receptor 
shared with thromboxane A,, mediating platelet activation 
and vasoconstriction (Pig. I) (16.17). Thus, the balance 
between prostaglandin endopemxide redirection and activa- 
tion of Lhromboxane AJPGH, receptors by prostaglandin 
endoperoxides themselves may influence the net effect of 
thromboxane A, synthase inhibitors in protecting ischemic 
myocardium. 
To determine whether these mechanisms play a role in 
influencing the fate of ischemic myocardium, we examined 
the effects of simultaneous inhibition of thromboxane A2 
synthase and blockade of thromboxane A,iPCiH, receptors 
on infarct size in a model of coronary occlusion followed by 
reperfusion and compared them with those obtained with 
either intervention alone. This study provides evidence of a 
role for prostagiandin endoperoxides in modtdaiing iiie ex- 
ten1 of myocardial injury in the presence of thromboxane A, 
synthase inhibition and identifies a pharmacologic interac- 
tion of potential therapeutic importance. 
Methods 
Experimental prepmratica. Forty-eight mate or female 
New Zealand White rabbits (4 to 4.5 kg) were studied. The 
experimental preparation has been described in detail else- 
where (18.19). Briefly, the rabbits were anesthetized with a 
mixture of ketamine (35 m&kg body weight) and xylazine 
(5 n&g) administered intramuscularly, intubated and ven- 
tilated with a constant volume respirator (Harvard Appara- 
tu?). Polyethylene catheters were placed into the aorta 
through the left carotid artery and into a jugular vein for 
monitoring arterial pressure and administration of drugs, 
respectively. A thoracotorny was performed throuqh the tifth 
left intercostal space and the pericardium opened. A poly- 
ethylene catheter was placed into the left atrium through the 
left atrial appendage for later injections of radioactive micro- 
spheres. The large marginal branch of the lefi circumflex 
coronary artery was temporarily occluded with a surgical 
suture snare approximately 0.3 cm frcen its origin. Coronary 
artery occlusion was maintained for 30 min. at which time 
the ligature was released and reperfusion allowed for an 
additional 5.5 h. Systemic arterial pressure (Statham P23 DB 
pressure transducer) was recorded continuously during the 
expriment (Gould Instruments). 
Pratacd. Fiien minutes before reperfusion, the rabbits 
were randomly assigned to one of the following treatment 
groups: a control group that received intravenous infusion of 
saline solution (n = IO); a group treated with SQ 29548 
(0.6-rnfig bolus injection, followed by a continuous infusion 
of 0.6 mgntg per h, n = 9), a Potent and selective thrombox- 
ane A#CH, receptor antagonist (Squibb Pharmaceuticals) 
(20,21); a group treated with dazoxiben (5-m& bolus 
injection, followed by a continuous infusion of 5 mgikg per h. 
n = 91, a selective thromboxane A2 synthase inhibitor 
(Dfizer Phamaceuticals) (22); a group treated with R 68070 
(Ridogre!, 20-m&g blus injection, followed by a continu- 
ous infusion of 20 m&g per h, n = 9). a drug with dual 
thromboxane A, synthase inhibiting and thromboxane AZ 
PGH, receptor-blocking properties (Janssen Research Foun- 
dation) Q3.24). and a group receiving aspirin (10 mglkg) and 
R 68070 at the same dose given to the group receiving 
R 68070 atone (n = 11). 
Assessment of area at risk, infarct size and na retlaw. To 
permit later assessment of the area at risk of infarction, 
2 X IO5 technetium-9Ym-labeled albumin microcphxcs 
W-pm diameter. 0%mCI activity) were injected into the left 
atrium 3 min after coronary artery occlusion. accordmg to a 
previously described techniqz (18.19). This technique ha3 
been shown to precisely idcnilfy the functional area at risk 
because it takes into account ihe valable mffow of blood 
from the unocclnded coronary bed through collaterdi vessels 
17% Um,,P.rr: 1_“,. b.“,,“,_., I -_-- “_ r___ h~rn~r. nhzrma:filnnir ~.‘rrvcfi[i,on~ r+! o._ ._. 
cause changes in the area at risk during the course of the 
experiment, a second measurement of the area at risk uaa 
obtained at the end of !be reperfusion period by evaluaring 
the Myocardial distribution of a solution of mona5tral blue 
dye injected into the left atrium. 
To estimate the distribtnion cftissuc perfusion at the end 
of the experiment (“no reflow” phenomenon). %rnnls re- 
ceived an injection ofa6% solution of thioflavillc t :: #@kg) 
through the left atria1 catheter according to a previouslv 
described technique (17.26). 
Immediately after injection of Ihiotlavine. the coronary 
artery was rcoccluded and a solution of mo;~stral blue dye 
@.I. DuPont; I mg/kg) was i,ljected through the left atrlal 
catheter. The heart was lhen immediatel; excised and the 
left ventricle dissected free from all ether strwtorcr zd 
weighed. The left ventricle mas frozen at -73°C for 30 z.;n 
and cuf into 8 to 10 slices parallel to the airioventricular 
groove. Contours of the normally perfused myocardium as 
well as the area at risk. according IO the distribution of 
monastnl blue dye. were traced onto a transparent plastic 
sheet. Myocardial slices were then observed under ultravi- 
olet light and contours of the fluorcscenl and nonlluorescenf 
(no reflow) areas were traced onto transparent plastic sheets. 
The slices were next incubaled in a 2% solution of rriphe- 
nyltetrazolium chloride (Sigma Chemicals) for 10 min at 3?“C 
(27) Agaain, a transparent Tlastic sheet v’as placed over the 
slices and the contours of these areas were traced. Therc- 
after, the extent of the ared at risk was gam determined on 
the same slices. according ;D the distribution of technerium- 
9%&b&d microspheres. Slices were placed in an X-ray 
film cassette over a sheet or high-speed X-ray film (Kodak 
HR) between 1wo medium contrast-enhancing screens. The 
film was exposed overnigti and developed. To clearlv iden- 
tify the overall contour of !he slices. “soft” X-ray (25 kV 
peak, 100 mA) images were obtained. with the slices held in 
position by the cassette. The W~I X-ray and autoradio- 
graphic images were superimposed to permit tracing of Ihe 
perfused (dark) and hhpoperfused (white) areas onto clear 
plastic overlays. The total cross-sectional area of the slices 
as well as of the area at risk, necrotic area and the area of DG 
reflow were determined by planimetry by an investigator 
who was unaware of the group assignmenl. 
The following variables were calcolated: II the area a, 
risk of infarction, as a percent of the left ventricle. assessed 
3 min after coronary occlusion (tecbnatiurr.-9Ymlabeled 
microqpheres) and ai the end of the r?pcrfusion period 
(monastrat blue dye distribution); 2) infarct size as a percent 
of the area at risk that actually evolved to necrosis by 
le~hr~tium-Wm-staining criterion; and 3) percent of the area 
al nsk that did not ;ccriv= blood Row at the end of !he 
reperfu<ion permd (no ref?ow phenomenon). 
Re$omal mysrrrdial hti llow ~~~~o~. Regional 
myacardlal blood ffow was measured in six rabbits in each 
lrcatment group. DitTerentially labeled plastic microspheres 
:srrontjum-85. scandium-46 and cobalt-57, New England 
Nuzarl were used to measure regional myocardial blood 
Row 20 min after occlusion and 10 min and 5 h after 
rcperfusion. Microspheres were- Ij ? I pn in size and 
suspen~kd in IO% d&ran solutionwit!! Q.I?l% Twecn 80. To 
ensure Lequatr dispersiop. tire microspheres were soni- 
cated man ultrasonic bath for 3 min immediately before use. 
Appronlmately 5OO.UOO microspheres were injected (9.5 10 
I ml to!al volume1 into the left atrial catheter. One minute 
before microsphere injection. reference arterial blood Row 
withdrawal was begun and continued for I min after rbc 
injection. Tissue samples (100 to 300 m;) from the center of 
the ischemx areas and fmm nonixhemic regions were takew 
according to triphenyltetrazolium staining. Myocardird and 
reference blood samples were counted in a gamma counter 
(Beckman A 500) at optimal window settings I week after Ihe 
evperimen: IO ensure complerc decay of technetium-99m 
activity. The counts per minure measured in each window 
From each myocardial and reference sample were corrected 
for overlapping counts of the accompanying isotopes (28). 
Regional myocardial biood flow to each sample was calcu- 
lated according (0 a previously described method (19) and 
expressed as mVmin per g of tissue. 
Prostaglandin measnremen~~. To assess the effects of 
drug treatments on endogenous prostaglandin production. 
serum formation of fhrombosane Bz, the stable metabolite of 
thrombonanc Al, was measured. Additionally, 6-kelo- 
PGF,,. the srabfe metabolite of PC&, and PCEz and FGF, 
levels were measured in plasma samples obtained from the 
arterial utheter immediately before and after 4 h of treat- 
mcnt. The catheter w,s filled with heparinized saline solu- 
tion immediately after placement and afrer each sample was 
obtained. After blood contained in the void space of the 
catheter was discarded. blood was allowed to flow directly 
into plain or chilled plastic tubes containing indomethacin 
I IO mg) and heparin (1,500 U). Blood in plain lubes was 
altowed to clot for I hat 37°C and then centrifuged at 4°C at 
2.W 8 for IO min. The serum was sepamted and stored 
frozen a( -70°C. Heparinized samples were immediately 
centrifuged at 4% at 2,WO R for IO min. and the plasma was 
separated and frozen at -70°C until assayed. Furthermore. 
to assess the effects of dazoxiben and R 68070on whole body 
thr;;nboxane A, synthesis, plasma levels of thromboxane B2 
were meahuredin eight additional rabbits not subjected to 
the coronary artery occlusion and reperfiision protocol. 
These animals were instrumented with polyethylene cathe- 
ters placed into a jugular vein and carotid artery. Blood 
samples wcrc collected as previously described into chilled 
plastic tubes containing indomethacin (IO mg) and heparin 
(1,500 U) at baseline and !5 min after administrrtion of either 
dazoxiben (n = 4) or R 68070 (n = 4). 
Radioimmunoassays of thromboxane B,, &keto-PGF,,, 
PGE, and PGF,, were performed on the nonextracted s~mm 
and plasma samples, respectively, using specific antisera and 
tritiated iracer: (291. Antisera aeainst thrnmboxane B, and 
dketo-PGF,, were raised in rabbits according fo the &hod 
of Bult et al. (30). Antisera against PGEz and PGF,, were a 
generous gift from Dr. Laekeman W.I.A. Antwem. Bel- 
&n). C&s-reactivity of the va&s antisera with;hrom- 
boxane Bz, Cketo-FGF,,, PGE,, PGF,,, PGDt, PGD,, 
PGF,,, PGE,, 13,14-dihydro-l5-k&o-PC&, 13,14-dihydro- 
IS-keto-PGF,, and arachidonic acid was always ~1.6%. 
Cross-reactivity of antisera for PGF,, with PGF,, and for 
PGE, with PGE, was 6.9% and 70%, respectively (23). 
Platelet aggregation. To evaluale the efficacy of drug 
treatments in inhibiting thromboxane A, synthase and block- 
ing throm&Aane A2/PGH2 receptors, platelet aggregation in 
response lo arachidonic acid and U46619, a thromboxane AZ 
mimetic, was performed ex viva. Blood samples were taken 
before and after 4 h of drug infusion. Blood (9 ml) was drawn 
in a syringe containing sodium citrate (I ml). Blood was 
centrifuged at 120 q for 20 min at room temperature to obtain 
platelet-rich plasma. This plasma was removed and centri- 
fuged at l,CiIO g for 5 min to olrtain platelet-poor plasma. 
Platelet agbqegation was measured turbidimetrically on a 
Chronolog aggregometor and recorded on a linear recorder. 
The aggregometer was calibrated with the use of platelet- 
poor plasma and the test was performed on 250 pl of 
platelet-rich plasma in a siliconized cltvette with continuous 
stirring. The platelet count in the platelet-rich plasma was 
adjusted to 3oO,ooO/~~ by dilution with platelet-poor plasma 
as needed. Aggregation was induced in platelet-rich plasma 
in response lo various concentrations of arachidonic acid 
and U-46619. 
In viva infusion of U44619. To assess whether SQ 29548 
and R 68070 resulted in a similar degree of thromboxane 
AJPGH? receptor blockade on vascular smooth mosclz. 
eight additional rabbits not subjected to the coronary artery 
occlusion-reperfusion profocol were used. In these animals, 
polyethylene catheters were placed into a jugular vein and 
the aortic root through the right carotid artery. Arterial 
blood pressure was continuously measured by means of a 
catheter placed into a femoral artery. Dose-response curves 
to U46619 were oblained by infusing increasing doses of the 
thromboxane A, mimetic (0.01.0.1, 1 and 10 &min) in the 
aortic root at baseline and were repeated 15 min after 
administration of either SQ 29548 (0.6~mglkg bolus injection, 
n = 4) or R 68070 (ZO-mglkg bolus injection, n = 4). 
S+atistical analyses. Results are expressed as mean value 
i SEM. Analysis of variance was used for multiple compar- 
isons among groups. Diffeb. Ices for individual groups were 
tested with a Student I tes: 4.r unpaired observations with 
the Bonferroni correction. r JT comparisons of prostaglandin 
measuremen!: a Student I test for paired observations was 
used. For comparisons of hemodynamic variables among 
Table 1. Hemcdynamic Variables During Coronary Anery 
Occlusion and Reperfusion 
Time 
Study Group 
hfw Aspirin + 
Occlusion Control SO 29548 Daraxiben R 68070 R 68070 
0 175 + 5 
30 mm 169 f 4 
Ih 169 + 6 
2h 173 * 5 
3h 170 t 4 
4h 175 f 5 
5h 175 * 5 
6h 168*4 
170 t 4 178 2 6 16925 112 t 5 
!64r6 168 + 4 
X6+5 165 t 5 
170 + 5 171 f 4 
!t8?6 178~ 5 
169I5 170 f 4 
I12 ? 6 17124 
I68 * 5 170+5 
groups, a rwo-way analysis of variance with a design for 
repeated measures was used. 
RE!SUltS 
Forty-eight rabbits underwent the surgical procedure; 
five died during coronary occlusion for ventricular fibrilla- 
tion (two in the aspirin-treated group and one each in the 
control, SQ 29548 and R 68070 groups). Three additional 
rabbits died during reperfusion (one each in the control, 
dazoxiben, and aspirin t R 68070 groups). 
Hemodynamic mensuremeols (Table 1). In all treatment 
groups, coronary occlusion induced a slight decrease in 
heart rate and mean arterial pressure. No differences in heart 
rate and mean arterial pressure were found among Ihe five 
groups during the course of the experimental period. 
Assessment of infarcl size and the no reflow phenomenon 
(Table 2, Fig. 2). Coronary occlusion produced an area at 
Table 2. Areas at Risk of Infarction E’rcduced by Comnery 
Arterv Occlusion 
Aspirin + 
Conlrul SY 29548 Duoxiben RML070 It68070 
AR-l WV) 31.1 f 1.6 29.9 L 1.0 30.9 I 1.2 29.6 + 1.0 30.1 2 1.2 
AR-2 (%LV) 30.9 5 1.7 10.3 * t.0 30.6 I 1.2 30.6 i I.2 ,0.9 + 1.1 
A?-I = area at risk tpercenl of Ml ventnck ILVI) measured 3 min&r 
con: dy occlusion by Icchnetium-Wm-labeled albumm mlcrmpherer: 
AR-2 = nrca~t risk tpercem all& ventricle) measured by monastml blue dye 
at Ihe end aftbe experiment ,ree text for detilr). 
Figure 2. PIor of infarct size (IS) and the area of no reflow [NR) at 
the end of the reperfusion period, expressed ar a percent ofthe area 
at risk of infarction. Dawxiben (DAZE. a xlect~~e thromboxane A, 
synlhase inhibitor. caused a significant redustion in both inlarct size 
and 1% area oi no reflow compared with values in control rabbits 
(COW The dual lhromboxane A? synthase and receptur blocker. R 
68070 (MB), caused a further reduc ion in infarct size and no rctluw 
compared wilh values in dazorihes-treated rabbits. These protec- 
tive etTects were completely abolished when aspirin was added lo R 
M1070 (ASA + R68). Blockade of lhromboxane AjPCH, receptors 
alone by SQ 29548 (SQ) did not signifxsntly affect these variables. 
Data are expressed as mean value = SEM. ‘p c O.QOl versus 
contml Ahits. **p < 0.01 versus dazoxiben-treated rabbits. 
risk of infarction, assessed by injection of technetiunG9m 
labeled microspheres 3 mitt afier occlusion, ranging from 
30% to 32% of the left ventricle in all treatroent groups. None 
of the drug treatments used in the present study caused any 
change in the area at risk during the course of the experiment 
because the areas at risk measured by injection of monastral 
blue dye at the end of the repetiiusion period were not 
diierent from values obtained 3 mitt after coronary occlu- 
sion. 
After 30 min of coronary occlusion and 5.5 h of reperfu- 
sion. an average of 57.7 + 3.2% of the area at risk had 
evolved toward necrosis in the control group. Administn- 
tion of SQ 29548 did not signiticantly reduce infarct size 
compared with that in control rabbits. Conversely, daToxi- 
ben administtation was associated with a significant reduc- 
tion in infarct size as compared with that in the control and 
SQ 29548 groups (p c 0.@401 vs. values in ~ntrol and SQ 
2954Ureated rabbits). Combined biockade of throtnboxane 
AJPGH, receptcrs anl inhibition of thromboxane A, syn- 
thaw by R 6x070 resulted in a further reduction in infarct 
size in dazoxiben-treated rabbits (p < O.Qi). The protective 
effects of R 68070 were completely abolished when the drug 
was admmtstexd with aspirin, as infarct size in this group 
avenged 39.7 ? 1.6% (p = NS vs. control animals). 
In control rabbits. 26.4 2 2.7% of the area at risk showed 
a perfusion defect, as determined by thioflavine S distri- 
bution at the end of the experiment. The extent of this 
area of no reflow was significantly reduced by dazoxiben and 
R 68070 compared with that in the control. SQ 29548 a.qd 
aspirin - R 68070 groups. Again, R 68070 rest&d in a 
further reduction in the area of no reflow as compared with 
that in the dazoriben-treated group, whereas aspirin treat- 
menf completely abolished the beneficial etfects of R 63070. 
Regional InylXWiiat Bosr -eaeati (T&te 3). 
In control r-4bbits. regional myccardird blood Row to the 
nonischemic mgocardium aver.tged I.2 mtAnin perg of tissue 
throughout the study. In this group, regional myocardii 
blood flow to the ischemic myocardium was O.oB * 0.02, 
1.43 T 0.28 and 0.98 2 0.19 mumin pet g of tissue 20 min 
after coronary occlusion and 10 min and 5 h after rep&u- 
sion, respectively. The various drug treatments used in the 
present study did not significantly change regional mycear- 
dial blood flow during the experimental period in normal or 
ischemic myocardium compared with that in controi ani- 
mals. 
Prostaglandin measurements. Serum thromboxane B1 
formation averaged 155 c 30 ng/rnl in control rabbits under 
basehne conditions and did not change signitlcantly after 4 h 
of infusion of saline solution (Fig. 3). Siiarly, plasma 
levels of &keto-PGF,,, the stable metabolite of FGI,, and 
PGE, and ffiF,,did not significantly change over the conrse 
of the experiment in control animals compared with corre- 
sponding baseline values (Fig. 4). Funhermore, both serum 
thrombonane 8, formation and plasma levels of 6-keto- 
FGF,,, FGE, and PGF,, did not significantly change before 
or during infusion of SQ 2954g (Fig. 3 and 41, thus co&tning 
that this drug did not exert any significant effect on 
prostaglandin synthesis. In contrast, serum thromboxane 
6: formation was virtually abolished in the dazoxiben-, 
Table 3. Regional Myaxdial Blood Flow (ml/min per g of tissue) During Camnary Artery Occlurion and Rep&&n 
COlltrOl SO 29548 Dazoxiben RMl70 Aswin * R w70 
Figure 3. Serum thrombonane B, (TXB,) formation in blood sam- 
ples obtained hcforc and aner drug adminirtration. Daroxiben 
(DAZ), R 6Ktl7ll (R6R) and the combination of aspirin and R 68070 
(ASA + R68) vinually abolished the formation ofthromboxane 3, 
compared with the corresponding baseline values. whereas SQ 
29548 (SQ) did not affect this variable. Data arc expressed as mean 
vdue + SEM. *p < O.Wi versus the corresponding baseline V&K 
CON = contrul rabbits. 
R 68070- and aspirin + R 68070 groups Wig. 31. Dazoxiben 
and R 68070 treatment also induced a concomitanl increase 
in plasma levels of 6-keto-PGF,,, PGE, and PGF*,. This 
effect was not observed when aspirin was added to R 68070 
(Fig. 4). 
In eight additional rabbits, plasma thromboxane 8, levels 
(as an index of whole body lhromboxane A2 production) 
were measured before and after administration ofdazoxiben 
or R 68070. At baseline study, thromboxane B, plasma levels 
nvrraged 77.9 f 6.! rind 73.i i 4.0 pgiml m animals 
subsequently treated with dazoxiben and R 68070, respec- 
tively. Plasma thromboxane R, levels decreased to 1 I .7 r 
2.6 and 10 14.5 + 3.9 pglml IS min after administration of 
dazoxiben and R 68070, respectively. The differences be- 
tween these groups were not statistically significant. 
Platelet aggregation. Ex viva platelet aggregation in re- 
sponse to various concentrations of arachidonic acid and the 
thromhoxane A2 mimetic U46619 was blocked during infu- 
sion of SQ 29548. R 68070 and aspirin t R 68070. In 
contrast, dazoxiben infusion did not alter platelet response 
to U46619 and onlv uartiallv inhibited aeereeation in re- . . _- I 
sponse to amchidonic acid (Fig. 5). These data indicate that 
R 66070 snd SQ 29548 at the doses used were effective in 
blocking thromboxane A,IPGH, receptors on platelets and 
that dazoxibcn is not a Lhromboxane A,IPGH, receptor 
antagonist. 
In viva infusion of U46619 (Table 4). The infusion of 
U46619 caused a dose-dependent increase in mean arterial 
blood pressure at baseline study in animals receiving this 
Lhromboxane A, mimetic. This increase in arterial blood 
pressure was similar in rabbits subsequently treated with SQ 
29548 or R 68C70 (from a baseline value of 66 f 7 and 64 it 
7 mm IIg to 90 * 8 and RX 5 6 mm Hg during infusion of 
10 &min of U46619, respectively). The response to U46619 
Figure 4. Plama prosraglandin (PG) levels (4ke@PGF,.. PGE, 
and PGF,,) in blwd samples obtained ln&re and after drug admin- 
iatrarian. Both dazoxiben @AZ) and R 68070 (R68) caused a 
signilicant increase in the form&ion of these prostaglandins with 
respect to the corresponding baseline values. When aspirin was 
added to R 68070 (ASA t Rabbi. no such increase was observed. SQ 
29548 (SQ) also did not induce an increase in the synthesis of these 
prostaglendins. Data are expressed as mean value t SEM. *p < 
0.01 versus the cocrcspondinp baseline value. C01i = control 
rabbits. 
was completely blocked in both groups al concentrations up 
II) 100 &min, thus demonstrating that the doses of two 
comoounds were similar in terms of blockade of vascular 
thromboxane A2/PGH2 receptors 
Discussion 
In the present study, the effects of SQ 29548 (a selective 
thromboxane A,IPGH, receptor antagonist). duzuxiicn (a 
selective thromboxanc A1 synthase inhibilor) and R 6aO7O 
(Ridogrel. a new drug with simultaneous thromboxane Az 
synthase-inhibiting and receptor-blocking properties) were 
studied in a rabbi1 model of myocardial isehemia- 
reperfusion. SQ 29548 did not significantly alter infarct sire 
and the no reflow phenomenon, whereas daroxiben caused a 
significant reduction in infarct size and the no reflow phe- 
nomenon compared with that in control rabbits. However, 
\IAI ‘,r.,< ,<-,n,,,,,,, 
Figure 5. In vitro platelei aggregation after drug administrdtic~n. 
Aggregation in response to U46619. a thromboxane A: mimrtic 
W~I), was inhibiled by SQ 29538 (SQL R 6WO CW! and qirin 
plus R 68070 (ASA + R68). whereas it was nol affected in daroxi- 
ben-treated mbbits (DAZ). Arachidonic acid-induced ag~,preganon 
(bottom) was completely inhibited by SQ 29548. R 68070 and aspinn 
plus R 68070, whereas it was only modestly affected by dazoxtben. 
MAX = maximal. 
simultaneou blockade of thromboxane AZIPGH2 receptors 
and inhibition of thromboxane AZ synthase (by R 680701 
resulted in n fuunher reduction in infarct size and rhc no 
reflow phenomenon. whirl? WC siynificandy greater that 
that observed in dazoxiben-treated rabbits. These protective 
effects of R 68070 were completely abolished when this drug 
was administered after aspirin. These data demonstrate that 
prostaglandin endoperoxides may influence the extent of 
Table 4. Chattger in Arterial Blood Pressure as a Percent Change 
Fmm Baseline in Response to U46619 Before and After 
Administration of SQ 29548 or R 68070 
~~hemra-mduced myocardial injury in !he retImg of throm- 
bunane A, \ynthase inhibidon apd rhar simultaneous block- 
dd: ot lhromboxanc AzjPGHz ~ceptors and inhthiricn of 
thlomhorane .4. synthnse ir more &ectivc in w$ucing 
mfarct wc than-is either intervention given separately. In 
the grcwnt :I&. we iniriared the various trearments 15 min 
hefore reperfuwm. by which time a maximal blockade of 
ikombuwte AzITGHZ receptors was already achieved, a~ 
demonwatcd by !he fact that the response to in viva 
in&ion of ‘Llhhl9 was completely inhibited IS mm after 
admmlstrarmn of Sy 29248 or R 68070. These effects were 
alw pa 4cnt. ~1s demonstrated by the observation thar both 
wrum ihromhovane A? formation and cx viva plattlet ag- 
grqation in response IO 11466619 were ~till inhibited 4 h after 
rcperfwion 
Prebious studies. in the present study, blockade of 
rhrombvu~w i,'r"GH,,E~~pi~iij~:ons:7S~;29j48~=snot 
m intcr~cn!!on powerful enough to +ld significant myocar- 
dial proteclion III this eq&mental model. This finding IS in 
conIra,t \riIh previously ~por:cd s!udies (3 t-36) employing 
thrombovans 41/PC,HI re;epIor amagonists in th? petring of 
regional myowrdia! ischemia and reperfusion in a different 
model of m~ocardial datnage. In this regard. it is known that 
J significant reduction in infarct size can be achieved by 
ndmmwar~on of exogenous EW2 (37), PGE, (381. PGF,, 
139.dOl as neii as PG[, analogs (19.411. The mechanisms by 
which rhw prosranoids reduce the extent of ischcmic 
myocardial injury are not clear as yet. but a reduction in 
nsutrophil-medialed injury has been suggested (37,301). 
Other invcstigarors (42) have observed a prorective effececr of 
PGl:. even in neutrophil-free preparations of myocardial 
ischemm and have invoked a direct “cytoprotective” edct 
ofrhesc prostaglandins. It is worth emphasizing that in both 
our study and that of Mullane and Fomabaio (13, the 
beneficial effects of Ihromboxane A, synthase inhibition 
were abolished by concomitant adm&ration of aspirin. 
These observations further suppon the concept of the pros- 
taglandin endoperoxide “steal” as an mdiiect mechanism of 
myocardial protection with thromboxane AZ synt.h.?se inhib- 
irors. 
Advantages nf ~imultanenns tbrnrnboxane A, syntlwe SW! 
receptor blockade. -4s observed, R 68070 is a new drq rha: 
possewe% simultaneous thmmboxane A2 synihase-inhibiting 
and thromborane AaPGH> receptor-blocking propenies 
(13.24). Indeed. at the dose used in the present study. R 
68070 resulted in simultaneous blockade of thromboxane 
A2/PGH2 receptors and inhibition of lhrcmimame Az syn- 
thaw Tixs was evidenced by complete inhibition of platelet 
aggregation induced by arachidonic acid and U46619 and 
suppressmn oi the response to in viva infusion of I34666619 
and strum thromboxsne Az formation to an extent similar to 
that in aspirk- and dazoxiben-treated animals. The ohserva- 
lion thal R 58070, a dual thromboxane A, synthase Inhibitor 
and receptor antagonist. was more effective in reducing 
infarct size than either intervention alone alsa suggests that 
the cardioproteciiw effects of daroxibcn wcrc limited by 
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either incomplete inhibition of thromboxane A, formation or 
by the accumulation of prostaglandin endoperoxides. Pros- 
taglandin endopcroxides are precursors of thmmboxane A, 
in the cyclooxygenase pathway of arachidonic acid metaco- 
iism in platekts and of PGI, in endothclial cells (Fig. I). As 
evidence of a shunt of pmstaglandin endoperoxides, them 
was a marked increase in production of endogenous PC& (as 
detected by the plasma measurement of its stable metabolite 
6-keto-PGF,,), ab well as of PGE, and PGF,, concomitantly 
with the inhibition of thromboxane Az biosynthesis in rabbits 
treated with R 68070 and dazoxiben. Alternatively, pros- 
taglandin endoperoxidas may directly activate a receptor 
shared with thromboxane A, that induces pl.rtelet activation 
and vascular smooth muscle contraction (14). In vitro and in 
vivo studies (14,15,35,43,44) demonstrate that prostaglandin 
endoperoxides may substitute for the proaggrcgatory effect 
of thromboxane A, and overcome the effect of thromboxane 
AZ synthase inhibition on platelets. In view of the marked 
inhibition of serum thromboxane A, formation by dazoxiben 
and the similar decrease in plasmathromboxane B, levels (as 
an index of whole body thromboxane A, synthesis) observed 
in dazoxiben and R 68070~treated animals in this study, our 
data are consistent with the hypothesis that prostaglanclin 
endoperoxides may reduce the myocardial protection in- 
duced by thromhoxane A, synthase inhibition alone in this 
experimental model. 
In the present study. we aiso ;nvestigated the effects of 
the various intervrntion strategies on the extent of tissue 
perfusion in the postischemic myocardium at the end of the 
repelfusion period. Inhibition of thromboxane A2 synthase 
by dazoxiben resulted in a significant reduction in the extent 
of the no reflow area. This reduction was even kreater in R 
6Xl70-treated rabbits, whereas SQ 29548 was without effects 
with respect tn results in control rabbits. The reduction in 
the extent of the no reflow areas was not accompanied by 
significant differences in postischemic blood flow among the 
various groups. Thus finding is not entirely unexpected 
because tissue samples taken transmurally and ‘*blindly” 
with respect to thioflavine staining invariably contain a 
mixture of low flow zones together with areas of normal and 
even hyperemic flow (45). Thus, average coronary blood 
Row in such tissue may not vary significantly despite signif- 
icant changes in the extent of the no reflow areas (4s). It is 
therefore conceivable that transmural tissue samples taken 
blindly from postischemic areas will show an average flow 
that reflects the relative contribution of these hypercmic 
areas and underperfused areas. 
Liiitations of the study, The data from the present study 
cannot rule out ivith certainty the possibility that R 68070 
was more effective than SQ 29548 and dazoxiben in reducing 
infarct size in our model because of mechanisms other than 
thromboxane A, synthase and receptor blockade. However, 
we believe that this possibility is unlikely for the following 
reasons. First, R 68070 does not significantly affect the 
response to a number of substances, such as platelet- 
activating factor, serotonin, epinephrine, adenosine diphos- 
phate, PGI,, POD,, PM,, dopamine, acetylcholine and 
histamine (23; De Clerk et al. unpublished observations). 
Second, the observation that concomitant administration of 
aspirin to R 68070-treated rabbits completely eliminated the 
protective effects of this compound strongly argues against 
this hypothesis. Another possible limitation of our observa- 
tions is that the effects of the various interventions were 
tested in an acute experimental model. Therefore, it cannot 
be established whether the protective effects seen with R 
68070 represent permanent salvage of myocardial tissue or 
whether the drug only delayed the progression of cell death. 
Conclusions. The present study demonstrates that signif- 
icant myocardial protection can be achieved by simulta- 
neous blockade of thromboxane A$PGH, receptors and 
inhibition of thromboxane A, synthase with respect to either 
intervention alone. Prostaglandin endoperoxides appear to 
be important in blunting the beneficial effects of thrombox- 
ane A, synthase inhibition in this experimental model of 
coronary occlusion and reperfusion. However, in the prcs- 
ence of an inhibitor of thrombarane A2 synihase add a 
thromboxane A,/PClHe receptor antagonist, they can be 
metabolized to cardioprotective prostaglandins without ac- 
tivating the receptors shared with thromboxane A,. The 
functional importance of this prostaglandin endoperoxide 
steal can be demonstrated when aspirin is added to R f&070. 
In this case, because the arachidonic acid cascade is blocked 
at the cyclooxygenase level, no prostagfandins can be syn- 
thetized and the protective e5ects of R 68070 arc lost (Fig. 
1). The resulting synergistic interaction between thrombox- 
ane AJPGH, receptor blockade and inhibition of thrombox- 
ane A2 synthase obtained by R 68070 renders this compound 
of potential therapeutic importance because R 68070 has 
been shown to potentiate the thmmbolytic properties of 
tissue plasminogen activator in a canine model of coronary 
thrombosis (44). Whether this beneftcial effect may apply to 
patients with acute myocardird infarction receiving throm- 
bolytic therapy is not clear. hut this possibility should be 
evaluated. 
We Ihank James T. WilIerson. MD for his useful commonly in reviewing Ihe 
manuscriat 
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